Table 2.
The patient’s baseline clinicopathological data at overall PSA level, PSA ≤ 10 ng/ml and PSA > 10 ng/ml
| Characteristics | Overall PSA level | PSA ≤ 10 ng/ml | PSA > 10 ng/ml | P value |
|---|---|---|---|---|
| Total, n (%) | 610 (100%) | 253 (41.5%) | 357 (58.5%) | |
| age, years, median (IQR) | 70 (64, 75) | 68 (63, 73) | 71 (65, 77) | < 0.001a |
| fPSA/tPSA, median (IQR) | 0.13 (0.09, 0.19) | 0.16 (0.12, 0.21) | 0.12 (0.08, 0.18) | < 0.001a |
| PV, cm3, median (IQR) | 50.8 (35.7, 73.3) | 46.9 (33.5, 67.3) | 52.2 (37.8, 77.6) | 0.003a |
| PSAD, ng/ml/cm3, median (IQR) | 0.23 (0.13, 0.45) | 0.13 (0.09, 0.20) | 0.36 (0.22, 0.80) | < 0.001a |
| Location, n (%) | 0.006b | |||
| PZ | 259 (42.5%) | 91 (14.9%) | 168 (27.5%) | |
| TZ | 351 (57.5%) | 162 (26.6%) | 189 (31.0%) | |
| Lesion size, mm, median (IQR) | 13.9 (9.3, 20.1) | 11.4 (7.8, 15.2) | 16.1 (10.7, 22.8) | < 0.001a |
| LV(cm3), median (IQR) | 0.51 (0.21, 1.40) | 0.33 (0.15, 0.69) | 0.85 (0.31, 2.26) | < 0.001a |
| ISUP grade, n (%) | < 0.001b | |||
| Benign | 286 (46.9%) | 159 (62.8%) | 127 (35.6%) | |
| 1 | 57 (9.3%) | 29 (11.5%) | 28 (7.8%) | |
| 2 | 50 (8.2%) | 24 (9.5%) | 26 (7.3%) | |
| 3 | 59 (9.7%) | 17 (6.7%) | 42 (11.8%) | |
| 4 | 83 (13.6%) | 16 (6.3%) | 67 (18.8%) | |
| 5 | 75 (12.3%) | 8 (3.2%) | 67 (18.8%) |
PSA: prostate-specific antigen, PV Prostate volume, PSAD PSA density, TZ Transition zone, PZ Peripheral zone, LV lesion volume; ISUP International Society Of Urological Patheology
a Mann-Whitney U test, b Chi-square test